Sildenafil, an FDA-approved competitive inhibitor of cGMP-specific PDE5, enhances NO signaling, reducing pulmonary arterial pressure and promoting vasodilation, thereby alleviating PAH symptoms [35]. The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.